VOR / Vor Biopharma Inc. - Zgłoszenia SEC, Raport roczny, o pełnomocnictwie

SECURITIES PURCHASE AGREEMENT

SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 26, 2026, by and among Vor Biopharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

REGISTRATION RIGHTS AGREEMENT

REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 26, 2026, is entered into by and among Vor Biopharma Inc.

Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, MA 02116

CORRESP Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, MA 02116 May 4, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes RE: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333- 295346) Request for Acceleration of Effective Date Requested Date:  May 6, 2026 Requested Time: 4

LETTER

May 1, 2026 Jean-Paul Kress Chief Executive Officer Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, MA 02116 Re: Vor Biopharma Inc. Registration Statement on Form S-3 Filed April 27, 2026 File No. 333-295346 Dear Jean-Paul Kress: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini

General Information About The Annual Meeting And Voting Proposal No. 1 – Election of Two Class II Directors Corporate Governance Proposal No. 2 – Approval of Amendment and Restatement of the Vor Biopharma Inc. 2021 Amended and Restated Equity Incenti

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA

As filed with the Securities and Exchange Commission on April 27, 2026

S-3 Table of Contents As filed with the Securities and Exchange Commission on April 27, 2026 Registration No.

Security Type

Calculation of Filing Fee Tables S-3 Vor Biopharma Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial

Overview Our Strategy Vor Bio is executing a focused strategy to become a leading global company in autoimmune therapeutics. Our strategic priorities include: 1. Rapid Global Development of Telitacicept: We are advancing telitacicept through global P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The descriptions below of Vor Biopharma Inc.’s (“our” or “we”) common stock and provisions of our amended and restated certificate of incorporation (“Restat

EXPLANATORY NOTE PART II SIGNATURES POWER OF ATTORNEY

As filed with the U.S. Securities and Exchange Commission on March 30, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) (I.R.S.

Vor Biopharma Inc. Incentive Compensation Recoupment Policy

Exhibit 97.1 Vor Biopharma Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Vor Biopharma Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable In

Calculation of Filing Fee Tables Form S-8 Vor Biopharma Inc.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 Vor Biopharma Inc. Table 1: Newly Registered and Carry Forward Securities  Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carr

Vor Biopharma Inc. Non-Employee Director Compensation Policy Effective: March 10, 2026

Vor Biopharma Inc. Non-Employee Director Compensation Policy Effective: March 10, 2026 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Vor Biopharma Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his

REGISTRATION RIGHTS AGREEMENT

REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 26, 2026, is entered into by and among Vor Biopharma Inc.

Vor Bio Announces $75 Million Private Placement with TCGX

Vor Bio Announces $75 Million Private Placement with TCGX BOSTON, Mass., March 27, 2026 (GLOBE NEWSWIRE) – Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement. Vor Bio

FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. Item 3.02 Unregistered Sales of Equity Securities. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2026 VOR BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File

SECURITIES PURCHASE AGREEMENT

SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 26, 2026, by and among Vor Biopharma Inc.

13,876,032 Shares Common Stock

424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-293052 PROSPECTUS 13,876,032 Shares Common Stock This prospectus relates to the proposed resale from time to time by the selling stockholders named herein, together with any additional selling stockholders listed in a prospectus supplement (together with any of such stockholders’ donees, pledgees, transferees or other su

Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, MA 02116

CORRESP Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, MA 02116 February 2, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford RE: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333-293052) Request for Acceleration of Effective Date Requested Date: February 4, 2026 Reque

LETTER

January 30, 2026 Jean-Paul Kress, M.D. President, Chief Executive Officer and Chairman of the Board Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, MA 02116 Re: Vor Biopharma Inc. Registration Statement on Form S-3 Filed January 29, 2026 File No. 333-293052 Dear Jean-Paul Kress M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please

Security Type

Calculation of Filing Fee Tables S-3 Vor Biopharma Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial

As filed with the Securities and Exchange Commission on January 29, 2026

S-3 Table of Contents As filed with the Securities and Exchange Commission on January 29, 2026 Registration No.

Global Science. One Purpose. 44th Annual J.P. Morgan Healthcare Conference January 2026

Global Science. One Purpose. 44th Annual J.P. Morgan Healthcare Conference January 2026 Forward Looking Statement This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “anticipate,” “believe,” “can,” “could,” “design,” “enabl

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 VOR BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fil

December 31, 2025

December 31, 2025 Qing Zuraw [***] Re: Terms of Separation from VOR Biopharma Inc.

FORM 8-K Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2025 VOR BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi

SECURITIES PURCHASE AGREEMENT

SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 15, 2025, by and among Vor Biopharma Inc.

FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. Item 3.02 Unregistered Sales of Equity Securities. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2025 VOR BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi

REGISTRATION RIGHTS AGREEMENT

REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 15, 2025, is entered into by and among Vor Biopharma Inc.

Vor Bio Announces $150 Million Private Placement

Vor Bio Announces $150 Million Private Placement BOSTON, Mass., December 15, 2025 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional a

FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 05, 2025 VOR BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi

50,999,711 Shares Common Stock

424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-290490 PROSPECTUS 50,999,711 Shares Common Stock This prospectus relates to the proposed resale from time to time by the selling stockholders named herein, together with any additional selling stockholders listed in a prospectus supplement (together with any of such stockholders’ donees, pledgees, transferees or other su

AMENDMENT TO EMPLOYMENT AGREEMENT

Exhibit 10.6 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), is made and entered into as of November 2, 2025 (the “Amendment Effective Date”), by and between Vor Biopharma Inc. (the “Company”) and Qing Zuraw (“Executive”), and amends the Employment Agreement by and between the Company and Executive, dated July 17, 2025 (the “Existing Agreement”). In con

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

10,000,000 Shares Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-285969 Prospectus supplement (To prospectus dated March 31, 2025) 10,000,000 Shares Common Stock We are offering 10,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “VOR.” On November 10, 2025, the last reported sale price of our common stock on The Nasdaq

FORM 8-K Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 VOR BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi

(b) The Company has complied and will comply with the requirements of Rule 433 under the Act applicable to any Issuer Free Writing Prospectus, including timely filing with the Commission or retention where required and legending; and the Company repr

VOR BIOPHARMA INC. Common Stock, par value $0.0001 per share Underwriting Agreement November 10, 2025 J.P. Morgan Securities LLC Jefferies LLC Citigroup Global Markets Inc. TD Securities (USA) LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison

Subject to completion, dated November 10, 2025

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-285969 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities and we are not soliciting an offer to buy these securiti

As filed with the Securities and Exchange Commission on November 10, 2025

S-3/A Table of Contents As filed with the Securities and Exchange Commission on November 10, 2025 Registration No.

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer BOSTON, Mass., November 3, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Dr. Sokolove brings more than two decades of clinical and translational experience in rh

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 02, 2025 VOR BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi

Global Science. One Purpose. 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sjögren’s Disease October 28, 2025

Global Science. One Purpose. 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sjögren’s Disease October 28, 2025 Forward Looking Statement This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “antic

FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025 VOR BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fil

LETTER

September 30, 2025 Jean-Paul Kress, M.D. President and Chief Executive Officer Vor Biopharma Inc. 500 Boylston Street, Suite 1350 Boston, Massachusetts 02116 Re: Vor Biopharma Inc. Registration Statement on Form S-3 Filed September 24, 2025 File No. 333-290490 Dear Jean-Paul Kress M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to

As filed with the Securities and Exchange Commission on September 24, 2025

S-3 Table of Contents As filed with the Securities and Exchange Commission on September 24, 2025 Registration No.

Security Type

Calculation of Filing Fee Tables S-3 Vor Biopharma Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial

As filed with the U.S. Securities and Exchange Commission on September 24, 2025

S-8 As filed with the U.S. Securities and Exchange Commission on September 24, 2025 Registration No. 333-    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organizatio

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 Vor Biopharma Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.0001 per share, reserved for issuance pursuant to the Amended and Restated 2021 Equity

. ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK cPAR VALUE $0.0001 Certificate Shares Number ** 000000 ****************** ZQ00000000 *** 000000 ***************** **** 000000 **************** VOR BIOPHARMA INC. ***** 00

EX-4.5 Exhibit 4.5 . ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK cPAR VALUE $0.0001 Certificate Shares Number ** 000000 ****************** ZQ00000000 *** 000000 ***************** **** 000000 **************** VOR BIOPHARMA INC. ***** 000000 *************** ****** 000000 ************** INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE ** Mr. Alexander David Sampl

PO PAR VALUE $0.0001MR ADDADDADDADD 4321 A BoxDESIGNATIONSAMPLE 43004, Certificate Shares(IF Number ** 000000 ****************** ANY) ZQ00000000 *** 000000 ***************** **** 000000 **************** Providence ***** 000000 ***************RI VOR B

EX-4.5 Exhibit 4.5 PO PAR VALUE $0.0001MR ADDADDADDADD 4321 A BoxDESIGNATIONSAMPLE 43004, Certificate Shares(IF Number ** 000000 ****************** ANY) ZQ00000000 *** 000000 ***************** **** 000000 **************** Providence ***** 000000 ***************RI VOR BIOPHARMA INC. ****** 000000 **************INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE02940 ** Mr. Alexander David Sample *

CERTIFICATE OF AMENDMENT AMENDED AND RESTATED CERTIFICATE OF INCORPORATION VOR BIOPHARMA INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware)

EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VOR BIOPHARMA INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Vor Biopharma Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation La

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2025 Vor Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or other jurisdiction of incorporation) (Commission F

144

144 0002050755 XXXXXXXX LIVE 0001817229 Vor Biopharma Inc. 001-39979 100 CAMBRIDGEPARK DRIVE SUITE 101 CAMBRIDGE MA 02140 617-655-6580 Reprogrammed Interchange LLC 10% Stockholder Common Audrey skillern 805 saint johns dr mansfield tx 76063 Mansfield TX 76063 23000000 46115000.00 126683111 09/03/2025 NASDAQ Common 12/26/2024 Private Placement Company N 23000000 12/26/2024 cash/check Y 09/02/2025 /

Forward Looking Statement This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “a

EX-99.1 Global Science. One Purpose. Corporate Presentation September 2025 Exhibit 99.1 Forward Looking Statement This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “anticipate,” “believe,” “can,” “could,” “design,” “enabl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Vor Biopharma I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi

Up to $119,699,305 Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-285969 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 31, 2025) Up to $119,699,305 Common Stock We have entered into a Sales Agreement, or the sale agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, dated December 23, 2022, relating to the sale of shares of our common stock, $0.0001 par value per shar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 Vor Biopharma Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File

VOR BIOPHARMA INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 28, 2025 APPROVED BY THE STOCKHOLDERS: AUGUST 25, 2025

EX-10.1 Exhibit 10.1 VOR BIOPHARMA INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 28, 2025 APPROVED BY THE STOCKHOLDERS: AUGUST 25, 2025 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 7 6. ADJUSTMEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 Vor Biopharma Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File

Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential

Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential.

500 BOYLSTON STREET BOSTON, MA OFFICE LEASE AGREEMENT 500 BOYLSTON & 222 BERKELEY OWNER (DE) LLC, a Delaware limited liability company, AS LANDLORD VOR BIOPHARMA, INC., a Delaware corporation, AS TENANT

Exhibit 10.10 500 BOYLSTON STREET BOSTON, MA OFFICE LEASE AGREEMENT BETWEEN 500 BOYLSTON & 222 BERKELEY OWNER (DE) LLC, a Delaware limited liability company, AS LANDLORD AND VOR BIOPHARMA, INC., a Delaware corporation, AS TENANT OFFICE LEASE AGREEMENT TABLE OF CONTENTS 1. Basic Lease Information. 1 2. Lease Grant. 3 3. Term and Commencement Date. 4 4. Rent. 5 5. Compliance with Laws; Use. 5 6. Gua

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 Vor Biopharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File N

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

EX-99.1 Exhibit 99.1 Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer July 17, 2025 • Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio’s new development focus and execution of late-stage programs CAMBRIDGE, Mass., J

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

EX-99.2 Exhibit 99.2 Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors July 21, 2025 - New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transfor

Employment Agreement, dated as of July 17, 2025, by and between the Company and Qing Zuraw

EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on July 17, 2025 by and between Qing Zuraw (the “Executive”) and Vor Biopharma Inc. (the “Company”). The Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive’s personal services to the Company; and Executive wishes to be employed by the Company an

Employment Agreement, dated as of July 9, 2025, by and between the Company and Sandesh Mahatme.

EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on July 9, 2025 by and between Sandy Mahatme (the “Executive”) and Vor Biopharma Inc. (the “Company”). The Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive’s personal services to the Company; and Executive wishes to be employed by the Company

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

EX-99.1 Exhibit 99.1 Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer • Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company’s transformation and growth in autoimmune disease CAMBRIDGE, Mass., July 10, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-sta

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

EX-99.1 Exhibit 99.1 Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset -Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis -RemeGen receives initial payment of $125 million consisting of an upfront payment

Vor Bio Announces $175 Million Private Placement

EX-99.2 Exhibit 99.2 Vor Bio Announces $175 Million Private Placement CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “PIPE”) that is expected to result in

Form of Securities Purchase Agreement, dated June 25, 2025, by and between the Company and Yantai Rongpu Investment Partnership (Limited Partnership).

Exhibit 10.2 Portions of this agreement (indicated by “[***]”) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 25, 2025, by and among Vor Biop

Form of Pre-Funded Warrant to Purchase Common Stock

EX-10.1 Exhibit 10.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES

Transition Agreement, dated as of June 25, 2025, by and between the Company and Robert Ang.

Exhibit 10.6 June 25, 2025 Robert Ang Via Email Re: Transition Agreement Dear Robert: This letter sets forth the substance of the separation agreement (hereinafter, “Agreement”) which Vor Biopharma Inc. (hereinafter, “the Company”) is offering to you to aid in your employment transition. 1. Transition Period. You have tendered, and the Company hereby accepts, your resignation from your role as Chi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Vor Biopharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File N

Form of Support Agreement, dated June 25, 2025, by and between the Company and the stockholders named therein.

EX-10.5 Exhibit 10.5 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is entered into as of June 25, 2025 by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and the stockholder of the Company named on the signature page hereto (the “Stockholder”). RECITALS A. Concurrently with the execution and delivery of this Agreement, the Company is enteri

Form of Securities Purchase Agreement, dated June 25, 2025, by and between the Company and the investors named therein.

Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 25, 2025, by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering this

Form of Registration Rights Agreement, dated June 25, 2025, by and between the Company and the investors named therein.

Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 25, 2025, is entered into by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used here

Employment Agreement, dated as of June 25, 2025, by and between the Company and Jean-Paul Kress.

EX-10.7 Exhibit 10.7 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on June 25, 2025 by and between Jean-Paul Kress (the “Executive”) and Vor Biopharma Inc. (the “Company”). The Company desires to employ Executive and, in connection therewith, to compensate Executive for Executive’s personal services to the Company; and Executive wishes to be employed by the Compa

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VOR BIOPHARMA INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Vor Biopharma Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), do

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 Vor Biopharma Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Exhibit 99.1 Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value CAMBRIDGE, Mass., May 8, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved

Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 Vor Biopharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) 181 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted

VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140

VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 March 27, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill Re: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333- 285969) Request for Acceleration of Effective Date Requested Date:  March 31, 2025 Requested T

LETTER

March 26, 2025 Robert Ang Chief Executive Officer Vor Biopharma Inc. 100 Cambridgepark Drive Suite 101 Cambridge, MA 02140 Re: Vor Biopharma Inc. Registration Statement on Form S-3 Filed March 20, 2025 File No. 333-285969 Dear Robert Ang: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceler

Power of Attorney (included on the signature page of this registration statement)

Table of Contents As filed with the Securities and Exchange Commission on March 20, 2025 Registration No.

VOR BIOPHARMA INC. INSIDER TRADING AND WINDOW PERIOD POLICY

Exhibit 19.1 VOR BIOPHARMA INC. INSIDER TRADING AND WINDOW PERIOD POLICY I. Introduction This policy determines acceptable transactions in the securities of Vor Biopharma Inc. (the “Company”) and other publicly-traded companies by our employees, directors and consultants who may become aware of material non-public information (“designated consultants”). During the course of your employment, direct

Vor Biopharma Inc. Incentive Compensation Recoupment Policy

Exhibit 97.1 Vor Biopharma Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Vor Biopharma Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable In

As filed with the U.S. Securities and Exchange Commission on March 20, 2025

As filed with the U.S. Securities and Exchange Commission on March 20, 2025 Registration No. 333-    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) (I.R.

Form of Preferred Stock Warrant Agreement and Warrant Certificate

Exhibit 4.7 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VOR BIOPHARMA INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vor Biopharma Inc.

100 Cambridgepark Dr, Suite 101 | Cambridge, MA 02140 | vorbio.com

Exhibit 10.17 October 4, 2022 Eyal Attar Dear Eyal: On behalf of Vor Biopharma Inc. (“VOR” or the “Company”), I am delighted to offer you the exempt position of Chief Medical Officer, reporting to Robert Ang, President and Chief Executive Officer. Your effective date of hire as an employee will be October 11, 2022, unless another date is agreed to by you and the Company. Your compensation for this

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per share, reserved for issuance pursuant to

Form of Debt Securities Warrant Agreement and Warrant Certificate

Exhibit 4.8 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VOR BIOPHARMA INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the l

Form of Debt Indenture between the Registrant and one or more trustees to be named

Exhibit 4.4 VOR BIOPHARMA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF [•], 20 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section

Form of Common Stock Warrant Agreement and Warrant Certificate

Exhibit 4.6 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VOR BIOPHARMA INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of

Exhibit 4.3

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The descriptions below of Vor Biopharma Inc.’s (“our” or “we”) common stock and provisions of our amended and restated certificate of incorporation (“Restated Certificate”) and amended and restated bylaws (“Bylaws”) are summaries and are qualified by reference to our Rest

EX-99

EX-99 2 exhibit99.txt Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA Fidelity Management Trust Co

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fil

125,710,335 Shares Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-284380 PROSPECTUS 125,710,335 Shares Common Stock This prospectus relates to the proposed resale from time to time by the selling stockholders named herein, together with any additional selling stockholders listed in a prospectus supplement (together with any of such stockholders’ donees, pledgees, transferees or other success

LETTER

January 27, 2025 Robert Ang President and Chief Executive Officer Vor Biopharma Inc.

VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140

VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 January 27, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333-284380) Request for Acceleration of Effective Date   Requested Date:    January 29, 2025   Re

As filed with the Securities and Exchange Commission on January 21, 2025

Table of Contents As filed with the Securities and Exchange Commission on January 21, 2025 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Vor Biopharma Inc.

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

EX-99.1 Exhibit 99.1 Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors CAMBRIDGE, Mass., January 8, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio’s Board o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Vor Biopharma Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File

JOINT FILING AGREEMENT

EX-99.1 2 ex-99-01072025090100.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of January 7, 2025, is by and among Reprogrammed Interchange LLC and Reid Hoffman (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G a

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of December 30, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedu

Form of Registration Rights Agreement.

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 26, 2024, is entered into by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used

Form of Common Stock Warrant.

Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REG

Vor Bio Announces $55.6 Million Private Placement Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylo

Exhibit 99.1 Vor Bio Announces $55.6 Million Private Placement Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 Extends cash runway through release of updated data from VBP101 and VBP301 trials in 2025 CAMBRIDGE, Mass

Form of Securities Purchase Agreement.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 26, 2024, by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are executing and delivering thi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2024 Vor Biopharma I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi

Disclaimer This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “anticipat

Exhibit 99.2 Ambition: Curing Blood Cancers through cell and genome engineering 1 December 2024 Disclaimer This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “anticipate,” “believe,” “can,” “could,” “design,” “enable” “est

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 Vor Biopharma In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fil

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Exhibit 99.1 Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design • Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplant • Trem-cel + Mylotar

VOR / Vor Biopharma Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment

SC 13G/A 1 tm2427604d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Vor Biopharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 929033108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this statement) Che

Offer Letter, by and between the Registrant and Han Choi, dated September 19, 2024

Exhibit 10.1 September 19, 2024 Han Choi Dear Han: On behalf of Vor Biopharma Inc. (“Vor Bio” or the “Company”), I am delighted to offer you the exempt position of Chief Financial Officer, reporting to Robert Ang, President and Chief Executive Officer. Your effective date of hire as an employee will be September 30, 2024 (“Start Date”), unless another date is agreed to by you and the Company. You

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Vor Biopharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission F

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

EX-99.1 Exhibit 99.1 Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer CAMBRIDGE, Mass., September 30, 2024 (GLOBE NEWSWIRE)—Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join t

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies

Exhibit 99.1 New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies • Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit • VCAR33ALLO demonstrates encouraging biomarker data at lowest dose • New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmu

This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “anticipate,” “believ

September 2024 Ambition: Curing Blood Cancers through cell and genome engineering Exhibit 99.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Vor Biopharma Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Amended and Restated 2021 Equity Incentive Plan

EX-10.1 Exhibit 10.1 VOR BIOPHARMA INC. AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN Adopted by the Board of Directors: MARCH 26, 2024 APPROVED BY THE STOCKHOLDERS: MAY 23, 2024 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 7 6. ADJUSTMENTS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Vor Biopharma Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Exhibit 99.1 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors CAMBRIDGE, Mass., May 2, 2024 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Researc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.___)

DEFA14A 1 d819945ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

ARS

f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(

As filed with the U.S. Securities and Exchange Commission on March 20, 2024

S-8 As filed with the U.S. Securities and Exchange Commission on March 20, 2024 Registration No. 333-      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization)

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) Security Type  Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value  $0.0001 per share,  reserved for issuance pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARM

VOR / Vor Biopharma Inc. / 5AM Ventures VI, L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vor Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) Paul A. Stone Chief Legal Officer 5AM Venture Management, LLC 501 2nd Street, Suite 350 San Francisco, CA 94107 (415) 99

VOR / Vor Biopharma Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment

SC 13G/A 1 tm245955d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Vor Biopharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 929033108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this statement) Check

VOR / Vor Biopharma Inc. / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 VOR BIOPHARMA INC COMMON STOCK Cusip #929033108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #929033108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,611,397 Item 6: 0 Item 7: 7,618,948 Item 8: 0 Item 9: 7

This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “anticipate,” “believ

January 2024 Ambition: Curing blood cancers through cell and genome engineering Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 Vor Biopharma Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fil

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform

Exhibit 99.1 Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform - Three oral and two poster presentations accepted by ASH - Company to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and Chief of the Hematologic Malignancies Program in the Division of Oncology

2023 Inducement Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Notice of Exercise, RSU Award Grant Notice and Award Agreement (RSU Award) thereunder

EX-99.1 Exhibit 99.1 VOR BIOPHARMA INC. 2023 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: AUGUST 25, 2023 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 2 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 6 6. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS 8 7. ADMINISTRA

As filed with the U.S. Securities and Exchange Commission on August 30, 2023.

As filed with the U.S. Securities and Exchange Commission on August 30, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) (I.R.S

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Vor Biopharma Inc.

VOR / Vor Biopharma Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 tm2323564d1sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* VOR BIOPHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform

EX-99.1 Exhibit 99.1 Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform • Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism. • Strong investigator enthusiasm and continued robust enrollment; additional data updates expected by year-end 2023. • U.S. FDA clears VCAR33ALL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Vor Biopharma Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 Vor Biopharma Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

Non-Employee Director Compensation Policy

Exhibit 10.1 Vor Biopharma Inc. Non-Employee Director Compensation Policy Effective: April 12, 2023 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Vor Biopharma Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation P

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 VOR BIOPHARMA INC.

As filed with the U.S. Securities and Exchange Commission on March 23, 2023

S-8 As filed with the U.S. Securities and Exchange Commission on March 23, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) (I.R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA

First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple MylotargTM Cycles at Initial Dose Level

Exhibit 99.1 First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple MylotargTM Cycles at Initial Dose Level • Trem-cel exhibited robust engraftment five months post-transplant through three cycles of Mylotarg • Mylotarg treatment enriched CD33-negative donor hematopoiesis • Second patient successfully received trem-cel transplant and achieved neutr

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi

VOR / Vor Biopharma Inc / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment

SC 13G/A 1 tm236410d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vor Biopharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 929033108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this statement) Check

VOR / Vor Biopharma Inc / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 VOR BIOPHARMA INC COMMON STOCK Cusip #929033108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #929033108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,970,488 Item 6: 0 Item 7: 7,970,511 Item 8: 0 Item 9: 7

Sales Agreement, dated December 23, 2022, by and between the Registrant and Stifel, Nicolaus & Company, Incorporated

Exhibit 1.1 Execution Version AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT December 23, 2022 STIFEL, NICOLAUS & COMPANY, INCORPORATED 787 Seventh Avenue, 11th Floor New York, New York 10019 Ladies and Gentlemen: Vor Biopharma Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Stifel, Nicolaus & Com

Up to $125,000,000 Common Stock

Table of Contents PROSPECTUS SUPPLEMENT (To Prospectus Dated March 18, 2022) Up to $125,000,000 Common Stock We have entered into a Sales Agreement, or the sale agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, dated December 23, 2022, relating to the sale of shares of our common stock, $0.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi

VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140

VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 December 16, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jason Drory Re: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333-268798) Request for Acceleration of Effective Date Acceleration Request Requested Date: Decemb

LETTER

United States securities and exchange commission logo December 15, 2022 Robert Ang, M.

Termination of a Material Definitive Agreement

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

As filed with the Securities and Exchange Commission on December 14, 2022

Table of Contents As filed with the Securities and Exchange Commission on December 14, 2022 Registration No.

Filing Fee Table

EX-FILING FEES 4 d432196dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vor Biopharma Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amoun

VOR / Vor Biopharma Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* VOR BIOPHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, A

15,302,267 Shares Common Stock

Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-263541 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 18, 2022) 15,302,267 Shares Common Stock We are offering 15,302,267 shares of our common stock at a purchase price of $4.30 per share. Our common stock is listed on The Nasdaq Global Select Market under the symbol “VOR.” The last reported sale price of our common stock on

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS

Underwriting Agreement, dated as of December 7, 2022, by and among Vor Biopharma Inc. and Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein

EX-1.1 2 d411199dex11.htm EX-1.1 Exhibit 1.1 Execution Draft VOR BIOPHARMA INC. Common Stock, par value $0.0001 per share Underwriting Agreement December 7, 2022 Evercore Group L.L.C. Stifel, Nicolaus & Company, Incorporated As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 c/o St

First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated MylotargTM

Exhibit 99.1 First AML Patient Successfully Transplanted with Vor Bio?s Investigational Trem-cel (VOR33) and Tolerated MylotargTM ? Trem-cel (formerly VOR33) successfully manufactured and engrafted normally ? Blood counts successfully maintained following post-transplant treatment with Mylotarg ? Conference call scheduled for today, December 7 at 8:00am ET CAMBRIDGE, Mass., Dec. 7, 2022 (GLOBE NEW

VBP101 Clinical Update December 7, 2022

Exhibit 99.2 VBP101 Clinical Update December 7, 2022 Disclaimer This presentation (the ?Presentation?) contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (?Vor,? ?Vor Bio? or the ?Company?) that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in thi

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

Exhibit 99.1 Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million CAMBRIDGE, Mass., Dec. 7, 2022 (GLOBE NEWSWIRE) ? Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fil

Securities Purchase Agreement, dated as of December 7, 2022, by and between the Registrant and RA Capital Healthcare Fund, L.P.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of December 7, 2022, between Vor Biopharma Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions se

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission Fi

VOR / Vor Biopharma Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* VOR BIOPHARMA INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

VOR / Vor Biopharma Inc / Paradigm Biocapital Advisors LP - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vor Biopharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 929033108 (CUSIP Number) October 17, 2022 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate the rule

Joint Filing Agreement

Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

Separation Agreement, by and between the Registrant and Christopher Slapak, dated May 11, 2022

Exhibit 10.1 May 11, 2022 Christopher Slapak, M.D. Via DocuSign/Email Re: Separation Agreement Dear Christopher: This letter sets forth the substance of the separation agreement (hereinafter, ?Agreement?) that Vor Biopharma Inc. (hereinafter, the ?Company?) is offering to you to aid in your employment transition and retirement from the Company. 1. Separation. Your last day of employment will be Ma

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 d268305ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File

LETTER

United States securities and exchange commission logo March 16, 2022 Robert Ang, M.

VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140

VOR BIOPHARMA INC. 100 Cambridgepark Drive, Suite 101 Cambridge, MA 02140 March 16, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Michael Davis Re: Vor Biopharma Inc. Registration Statement on Form S-3 (File No. 333-263541) Request for Acceleration of Effective Date Acceleration Request Requested Date: March 1

Form of Common Stock Warrant Agreement and Warrant Certificate

Exhibit 4.6 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VOR BIOPHARMA INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the laws of

As filed with the U.S. Securities and Exchange Commission on March 14, 2022

As filed with the U.S. Securities and Exchange Commission on March 14, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) (I.R.S.

As filed with the Securities and Exchange Commission on March 14, 2022

Table of Contents As filed with the Securities and Exchange Commission on March 14, 2022 Registration No.

Filing Fee Table

EX-FILING FEES 4 d326176dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule(1) Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(6) Equity Common Stock, par

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 VOR BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA

Open Market Sale AgreementSM, dated March 14, 2022, between the Registrant and Jefferies LLC

Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM March 14, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Vor Biopharma Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stock,

as updated by the description of our capital stock contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The descriptions below of Vor Biopharma Inc.?s (?we,? ?our? or ?we?) common stock and provisions of our amended and restated certificate of incorporation (?Restated Certificate?) and amended and restated bylaws (?Bylaws?) are summaries and are qualified by reference to ou

Form of Debt Securities Warrant Agreement and Warrant Certificate

Exhibit 4.8 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VOR BIOPHARMA INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the l

Form of Debt Indenture between the Registrant and one or more trustees to be named

Exhibit 4.4 VOR BIOPHARMA INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF [?], 20 DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certificate 6 Section

Form of Preferred Stock Warrant Agreement and Warrant Certificate

Exhibit 4.7 VOR BIOPHARMA INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF VOR BIOPHARMA INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VOR BIOPHARMA INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under th

VOR / Vor Biopharma Inc / FMR LLC Passive Investment

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 1 VOR BIOPHARMA INC COMMON STOCK Cusip #929033108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #929033108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 611,457 Item 6: 0 Item 7: 3,181,463 Item 8: 0 Item 9: 3,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

Second Amendment to Exclusive License Agreement, by and between the Registrant and The Trustees of Columbia University in the City of New York, dated November 8, 2021

EXHIBIT 10.1 Portions of this agreement (indicated by ?[***]?) have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential. SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT ("Second Amendment") is made and e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs

Exhibit 99.1 Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) - Vor Biopharma (Nasdaq: VOR or the Company) announced today that it will build-out an in-house clinical manufacturing facility in Cambridge, Massachusetts to support its development of potentially transformative engine

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission File N

First Amendment to Lease, by and between the Registrant and the Landlord, dated June 15, 2021

Exhibit 10.1 First Amendment to Lease This First Amendment to Lease (this ?Amendment?), is made as of the 15th day of June, 2021 (the ?Effective Date?), by and between PPF OFF 100 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company, with a business address of c/o Morgan Stanley Real Estate Advisor, Inc., 1585 Broadway, 37th Floor, New York, New York 10036 (the ?Landlord?) and VOR BIOPH

Second Amendment to Lease, by and between the Company and Landlord, dated June 15, 2021

Exhibit 10.2 Second Amendment to Lease This Second Amendment to Lease (this ?Amendment?), is made as of the 15th day of June, 2021 (the ?Effective Date?), by and between PPF OFF 100 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company, with a business address of c/o Morgan Stanley Real Estate Advisor, Inc., 1585 Broadway, 37th Floor, New York, New York 10036 (the ?Landlord?) and VOR BIO

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39979 VOR BIOPHARMA INC.

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39979 VOR BIOPHARMA

SC 13G

SCHEDULE 13G Amendment No. 0 VOR BIOPHARMA INC COMMON STOCK Cusip #929033108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #929033108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 764,153 Item 6: 0 Item 7: 3,935,238 Item 8: 0 Item 9: 3,935,238 Item 11: 10.60

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Vor Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) 5AM Venture Management, LLC 501 2nd Street, Suite 350 San Francisco, CA 94107 (415) 993-8565 (Name, Address and Telephone

Under the Securities Exchange Act of 1934 (Amendment ___)* Vor Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Vor Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 929033108 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, Address

Amended and Restated Certificate of Incorporation of the Registrant

EX-3.1 Exhibit 3.1 VOR BIOPHARMA INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Vor Biopharma Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: That the name of this corporation is Vor Biopharma Inc., and that this corporation was originally incorporated pursuant to the General Corporation Law of the S

Amended and Restated Bylaws of the Registrant

EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF VOR BIOPHARMA INC. (A DELAWARE CORPORATION) February 9, 2021 VOR BIOPHARMA INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of The Corporation Trust Company, 1209 Orange Street, in the City of Wilmington, County of New Castle, in the State of Del

Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares

EX-99.1 Exhibit 99.1 Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares CAMBRIDGE, Mass., Feb. 9, 2021 — Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the closing of its previously an

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 Vor Biopharma Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39979 81-1591163 (State or Other Jurisdiction of Incorporation) (Commission

Form of Nonstatutory Stock Option Agreement Granted Outside of 2015 Stock Incentive Plan

EX-4.7 Exhibit 4.7 VOR BIOPHARMA INC. Nonstatutory Stock Option Agreement Granted Outside of 2015 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Vor Biopharma Inc., a Delaware corporation (the “Company”), [], 2020 (the “Grant Date”) to [] (the “Participant”), of an option to purchase, in whole or in part, on the terms provided herein and subject to the terms of the

( File No. 333-252908)

S-8 As filed with the U.S. Securities and Exchange Commission on February 9, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vor Biopharma Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1591163 (State or other jurisdiction of Incorporation or organization) (I

9,828,017 Shares Common Stock

424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-252175 and 333-252766 PROSPECTUS 9,828,017 Shares Common Stock This is an initial public offering of shares of common stock of Vor Biopharma Inc. We are offering 9,828,017 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price per share

- S-1MEF

S-1MEF As filed with the Securities and Exchange Commission on February 5, 2021 Registration No.

-

begin 644 filename1 M)5!$1BTQ+C4-)>+CS],-"C0R(# @;V)J#3P\+TQI;F5A"R;M@$B(^!\QN!I/P2+K@"33LA8@ M^.

- 8A CERT

begin 644 8ACertVOR.pdf M)5!$1BTQ+C8-)>+CS],-"C0V(# @;V)J#3P\+TQI;F5AF4@.# O5'EP92]84F5F+U=;,2 S(#%=/CYS=')E86T-"FC>8F)D M8!!@8&)@8%H&(AFG@,EP$,DR%T1RK@;+/@&+*X%(CV-@$1,0F:P&%M< DHQV M9\'LYR"RX #"3!Y1$,G1!B(%NT DFRZ0)]TD8$):/M>D A0'T7D?P;&LU\! M @P 2R4110T*96YDRP<"37L.;^+/X!)KRX$9Q'@P 6(@LQ;<*!8&QBN+(**,J0 !!@#LK+SVFT=/YO*.%=[XA3VQ.I%0P:ZHM"O43.H]I\UCS7^L7DT9U1D4;$-5#,- MU&@9Z)UAH-(N[.C/2JK[3)!.\N

Form S-1

S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 3, 2021.